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Abstract
Background: Environmental challenges during development affect the fetal epigenome, but the period(s) vulnerable to
epigenetic dysregulation is(are) not clear. By employing a soy phytoestrogen, genistein, that is known to alter the
epigenetic states of the A
vy allele during embryogenesis, we have explored the sensitive period for epigenetic regulation.
The post-implantation period, when de novo DNA methylation actively proceeds, is amenable to in vitro analysis using a
mouse embryonic stem (ES) cell differentiation system.
Methods and Findings: Mouse ES cells were differentiated in the presence or absence of genistein, and DNA methylation
patterns on day 10 were compared by microarray-based promoter methylation analysis coupled with a methylation-
sensitive endonuclease (HpaII/McrBC)-dependent enrichment procedure. Moderate changes in methylation levels were
observed in a subset of promoters following genistein treatment. Detailed investigation of the Ucp1 and Sytl1 promoters
further revealed that genistein does not affect de novo methylation occurring between day 0 and day 4, but interferes with
subsequent regulatory processes and leads to a decrease in methylation level for both promoters.
Conclusion: Genistein perturbed the methylation pattern of differentiated ES cells after de novo methylation. Our
observations suggest that, for a subset of genes, regulation after de novo DNA methylation in the early embryo may be
sensitive to genistein.
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Introduction
In mammals, the intrauterine environment affects the fetal
epigenome. For example, maternal dietary genistein increases the
level of DNA methylation at the cryptic promoter derived from
intracisternal A-particle insertion in the agouti gene (the viable
yellow allele of agouti is denoted A
vy) [1]. This genistein-induced
hypermethylation of A
vy occurs to a similar extent in tissues from
all three germ layers (brain, liver, and kidney) and persists into
adulthood. Because A
vy undergoes epigenetic reprogramming after
fertilization [2], alteration of DNA methylation patterns by
genistein would probably occur within the developmental window
after fertilization but before germ layer differentiation [3].
During early embryonic development, approximately at im-
plantation, the DNA methylation patterns of individual promoters
dynamically change. For example, the methylation of specific sites
in Apoa1 is erased after fertilization; after implantation, methyla-
tion is restored by the gastrulation stage [4]. Recent genome-wide
analysis of promoter DNA methylation in the early embryo has
confirmed that de novo methylation occurs during implantation in
476/691 promoters that are methylated in the E9.5 embryo [5].
Of importance, DNA methylation patterns established around
implantation can be modified by further methylation or
demethylation during subsequent stages of organogenesis [5].
However, the influence of environment on DNA methylation
dynamics of intrinsic promoters is still unknown.
To clarify how environmental factors affect DNA methylation
dynamics, especially during the post-implantation period, we
characterized the alterations in DNA methylation patterns induced
by genistein in an embryonic stem (ES) cell differentiation system.
We developed a novel DNA methylation assay, MspI fragment-
based DNA methylation typing (MFMT), for use in combination
with a mouse promoter microarray to identify genistein-mediated
differentially methylated regions (DMRs). Of the 149 DMRs
identified, 54 regions were more methylated and 95 regions were
less methylated in genistein-treated cells than in control cells.
Among these DMRs, 74 regions were located proximal to the
transcriptional start site (TSS) of adjacent gene(s). The genistein-
mediated hypomethylation of the Ucp1 and Sytl1 promoters was
further analyzed for the effects of genistein on methylation
dynamics. Bisulfite sequencing confirmed the decrease in methyl-
ation levels of both promoters on day 10. Of interest, the
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and peak levels were equivalent in genistein-treated and untreated
cells. Thus, once de novo DNA methylation of these promoters was
complete,genisteinappeared toacceleratethe subsequent decline in
methylation levels. Our results suggest that genistein influences
DNA methylation established around the post-implantation period,
which may partly explain the vulnerability of the embryonic
epigenome to intrauterine environmental changes.
Materials and Methods
ES cell culture and differentiation
ES cells were maintained in Dulbecco’s Modified Eagle
Medium (Sigma, St. Louis, MO) with 15% fetal calf serum
(Millipore, Billerica, MA), 10
3 Um l
21 leukemia inhibitory factor,
0.1 mM MEM non-essential amino acids (Sigma), 16nucleosides
mix, 2 mM L-glutamine, penicillin/streptomycin, and 40 mM2 -
mercaptoethanol (Sigma). ES cell lines CCE (strain 129/Sv) and
E14Tg2a (strain 129/Ola), gifts of Dr. A. Miyajima (University of
Tokyo), are feeder-independent. For ES cell differentiation,
embryoid body (EB) formation was induced by hanging-drop
culture without leukemia inhibitory factor for 2 days, followed by 2
days of suspension culture and 6 days of culture on gelatinized
dishes. During differentiation, ES cells were treated with the
indicated concentrations of genistein (0, 1, 5, or 10 mM) dissolved
in dimethyl sulfoxide (DMSO); the medium was replaced every
other day. The final DMSO concentration in all the samples was
0.01% (v/v). From differentiation day 8 to day 12, the proportion
of EBs with contracting myocardiocytes was evaluated. Concen-
trations of up to 5 mM genistein did not impair cardiac
differentiation (Figure S1).
Real-time PCR analysis
Esr1, Esr2, Pou5f1, T, Fgf5, Wnt3a, Pdgfra, Tbx5, Gata4, and Gata6
mRNA levels were measured by real-time RT-PCR in a
LightCycler 480 (Roche Applied Science, Mannheim, Germany).
Total RNA was extracted from ES cells (day 0, day 4 of control,
day 4 of genistein-treated, day 10 of control, and day 10 of
genistein-treated) using the RNeasy mini kit (QIAGEN, Hilden,
Germany). After treatment with DNase I (Invitrogen, Carlsbad,
CA), cDNA was synthesized from 1 mg RNA per reaction with
200 U Superscript III, 2.5 mM oligo (dT)20, 0.5 mM dNTP,
5 mM MgCl2, and 10 mM DTT in reaction buffer (Invitrogen) at
50uC for 50 min. All reactions were run together with RT minus
controls. After termination of cDNA synthesis at 85uC for 5 min,
the reaction mixture was further incubated with RNase H at 37uC
for 20 min. Real-time PCR was performed using the LightCycler
480 Probe Master kit (Roche Applied Science) and the specific
primers and the corresponding Universal Probe Library probe
(Roche Applied Science) according to the manufacturer’s
instructions. The identification numbers of Universal Probe
Library probes and primer sequences are listed in Table S1.
Normalized gene expression values, calibrated with the value on
day 0, were obtained with LightCycler Relative Quantification
software (ver 1.5, Roche Applied Science) using Actb as a reference
gene (Figures S2 and S8).
Figure 1. Scatter plot of the log2 (HpaII
r/McrBC
r) values of control and genistein-treated samples for individual probes. The total
number of probes used in the MspI fragment-based DNA methylation typing assay is 127,857. The log2 (HpaII
r/McrBC
r) values for the individual
probes of dimethyl sulfoxide-treated (control) and genistein-treated samples were plotted. There was little variability in the log2 (HpaII
r/McrBC
r)
values of the same probe between the two samples. The regression line is purple; the cyan and yellow lines denote 2 and 3 standard deviations,
respectively, of the horizontal distance from the regression line.
doi:10.1371/journal.pone.0019278.g001
Epigenetic Effects of Genistein in ES Cells
PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e19278MspI fragment-based DNA methylation typing (MFMT):
assay and analysis
Genomic DNA was extracted from control cells (DMSO only)
and genistein-treated cells at day 10 of CCE differentiation using
the QIAamp DNA Mini kit (QIAGEN). A total of 200 ng of each
DNA sample was digested to completion for 3 h with 10 U MspI,
and the digested DNA was purified with the MinElute Reaction
Clean-up kit (QIAGEN). Two complementary oligonucleotides
(59-AGCACTCTCCAGCCTCTCACCGAC-39 and 59-CGGT-
CGGTGAGAGGCTGG-39) were annealed and ligated to the
MspI fragments, and their 39 ends were extended with Platinum
Taq DNA polymerase (Invitrogen, Carlsbad, CA) at 72uC for
15 min. The reaction mixture was then divided into three aliquots
and subjected to enzymatic digestion for 4 h. One aliquot was
treated with 10 U MspI, another with 10 U HpaII, and the third
aliquot with 10 U McrBC (Figure S3). Ligation-mediated PCR
(LM-PCR) was carried out for each product with the FastStart
High Fidelity PCR System (Roche, Mannheim, Germany) in
buffer containing 1.8 mM MgCl2, 2% DMSO, and the specific
primer 59 -GCCTCTCACCGACCGG-39. Amplification condi-
tions consisted of a hot start at 95uC for 2 min, followed by 26
cycles of 95uC for 20 s, 72.9uC for 20 s, and 73uC for 30 s; 18
cycles of 95uC for 20 s, 72.3uC for 20 s, and 73uC for 10 s; 8
cycles of 95uC for 20 s, 71.0uC for 20 s, and 73uC for 30 s; and
finally a hold at 72uC for 5 min. The quality of the LM-PCR
reaction was tested with the Agilent 2100 bioanalyzer (Santa
Clara, CA). PCR products were purified with a MinElute
Reaction Clean-up kit, and were labeled with Alexa 555 or 647
using the BioPrime Plus Array CGH Genomic Labeling System
(Invitrogen) in accordance with the manufacturer’s instructions,
with the exception of a use of 100 U Klenow fragment per labeling
reaction. The labeled PCR products were mixed and then
hybridized to the NimbleGen (Madison, WI) mouse 385K CpG
Island Plus Promoter Array (cat# 00893), according to the
manufacturer’s protocol. Hybridized arrays were scanned with a
NimbleGen MS200 Scanner, and the images were analyzed with
NimbleScan software (ver 2.6).
The NimbleGen mouse 385K promoter array contains 373,638
probes in total on average ,1.3 kb of upstream sequence and
,0.5 kb of downstream sequence from the TSS, covering 15,963
promoters/CpG islands. Each probe is 50–70 nucleotides in
length, with roughly 18 probes per region with 100–bp spacing.
We selected a subset of probes for our analysis (Figure S3). First,
we excluded the probes that contain the MspI recognition
sequence (CCGG). Next, because the LM-PCR products were
generated mainly in the 100–1000 bp size range, we focused on
probes enclosed by two MspI sites with an interval length between
100 and 1000 bp (Figure S3). Our selection criteria led to the
retention of 127,857 (34.2% of the total NimbleGen probes) for
further analysis.
If the CpG at the end of the MspI-digested fragment is methylated,
the adaptor-ligated product remains resistant to HpaII digestion, so
that the LM-PCR product (the HpaII-resistant product) can be fully
generated (Figure S3). If the MspI fragment contains McrBC target
CpGs(recognitionsequenceR
mC(N)55–103R
mC)andthoseCpGsare
methylated, the ligation product is sensitive to McrBC digestion,
leading to infrequent generation of the LM-PCR product (McrBC-
resistant product). Using the ChIP Compute Ratio Files Analysis in
the NimbleScan software, the log2 (HpaII
resistant(r)/McrBC
resistant(r))
values were calculated for individual probes. During this process, the
values were scaled to zero by subtracting the bi-weight mean for all
featuresonthe arrayfromeachlog2ratio. The log2(HpaII
r/McrBC
r)
value for each probe reflects the methylation level of the MspI
fragment in which the probe exists.
To evaluate the methylation detection performance of the
MFMT assay, we calculated the mean log2 (HpaII
r/McrBC
r)
values for the MspI fragments in several methylation-control
promoters. Because there was no precise information about the
promoter DNA methylation levels in day-10 differentiated ES
cells, we searched the possible candidates for universally (in
somatic cells) methylated or unmethylated promoter regions by
using previously published data [6]. For selection of the
methylated regions, we considered three criteria as follows: (1)
mean methylation levels assayed by RRBS (reduced representation
bisulfite sequencing) were high (.0.30) in ES, NPCs (neural
precursor cells), astrocytes, whole brain, CD4+ T cells, CD8+ T
cells, B cells, MEFs (mouse embryonic fibroblasts), tail-tip, liver,
spleen, and lung ([6]); (2) a germ-line–specific promoter was
present; and (3) the promoter region contained a pair of adjoining
MspI sites with an interval that was long enough to contain more
than two consecutive probes of the microarray and short enough
for LM-PCR to achieve the MFMT assay. Eventually, seven
regions of Dazl, Sycp1, Tuba3a, Spo11, Hormad1, AU022751, and
Sycp2 were selected as ‘‘methylation positive controls.’’ On the
other hand, for the unmethylated regions, we considered three
criteria as follows: (1) mean methylation levels assayed by RRBS
were low (,0.20) in all the samples analyzed by Meissner et al. [6];
(2) there was a ubiquitously expressed gene promoter; and (3) the
promoter or CpG island region contained a pair of adjoining MspI
sites with an interval length that was adequate for the MFMT
assay. Although over 2000 gene promoters met two criteria, such
as (1) and (2), less than half met a third criterion because of so-
called HpaII Tiny Fragments (HTFs) ([7]). Among these, we
selected 46 regions that are highly transcribed in ES cells as
‘‘methylation negative controls.’’ Figure S4 shows the scatter plot
of the mean log2 (HpaII
r/McrBC
r) values of untreated and
genistein-treated samples for these methylation control regions.
The blue dots represent methylation-positive whereas the red dots
indicate methylation-negative controls. Figure S5 shows the
detailed information about the four representatives of these
control regions (Dazl, Spo11, Dhfr, and Psmd1). Thus, the mean
log2 (HpaII
r/McrBC
r) values derived from the MFMT analysis
were substantially related to the CpG methylation levels, with
larger values reflecting higher methylation levels. Additionally,
little inter-microarray variability was observed among the log2
(HpaII
r/McrBC
r) values in the methylation-control regions,
consistent with a Pearson correlation coefficient of 0.923 for all
Table 1. Details of the relative positions of detected GEN-
mediated DMRs.
Regions with
decreased
methylation levels
after GEN exposure
Regions with
increased
methylation levels
after GEN exposure
More than 200 bp
upstream of nearest TSS
15 6
Less than 200 bp
upstream of nearest TSS
32 19
In gene-body regions 47 (16)* 28 (7)*
In intergenic regions 1 1
Total Number 95 54
GEN, genistein; DMR, differentially methylated region; TSS, transcription start
site;
*number of DMRs located in exon 1.
doi:10.1371/journal.pone.0019278.t001
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r/McrBC
r) probe values from the control and 5 mM
genistein-treated samples. All the statistical computation and
graphics were performed using the R Statistical Package (http://
www.r-project.org/). Gene ontology analysis was conducted using
the Database for Annotation, Visualization and Integrated
Discovery (DAVID) v6.7 [8].
Bisulfite sequencing
One microgram of genomic DNA from ES cells and tissues was
bisulfite converted with an EpiTect Bisulfite Kit (QIAGEN) using
a standard protocol. Bisulfite conversion of embryonic genomic
DNA was performed with the EZ DNA Methylation-Direct Kit
(Zymo Research, Orange, CA). Bisulfite sequencing primers are
Table 2. Methylation levels of 32 DMRs in promoters that decreased following GEN exposure.
Position Gene(s) Control GEN DM/T Class Ref.
chr4:134392301–134392772 Runx3 2.0160.58 0.2860.07 4/4 LCP M
chr18:24132054–24132434 Zfp35 1.7860.33 20.0160.35 3/3 ICP ND
chr12:84958869–84959299 Acot5 1.1760.40 20.0160.39 3/4 HCP ND
chr18:78758937–78759113 Slc14a2 0.7060.76 21.1960.02 2/2 LCP ND
chr14:53641194–53641417 Acin1-1700123O20Rik 0.3860.18 23.3660.03 2/2 HCP U
chr10:80787136–80787377 Dohh 0.3560.54 21.2960.37 2/2 HCP ND
chr15:41619452–41619822 Oxr1 0.1960.13 21.6661.37 2/3 HCP U
chr1:36218070–36218359 Neurl3 0.0160.66 21.4560.74 2/3 LCP ND
chr4:132534712–132535246 Sytl1 20.0360.48 21.1360.44 4/5 LCP I
chr12:45080426–45080612 Dnajb9 20.1160.25 22.8260.70 2/2 HCP U
chr1:12703475–12703685 Sulf1 20.1660.54 23.1960.53 2/2 LCP U
chr17:31895678–31896022 Notch3 20.1860.13 22.0460.05 3/3 HCP I
chr18:38727246–38727472 Spry4-9630014M24Rik 20.2060.54 21.7560.05 2/2 HCP U
chr13:74674934–74675272 Exoc3 20.2660.56 21.5360.81 3/3 HCP ND
chr15:84059440–84059681 Parvb 20.3360.42 22.3860.22 2/2 HCP U
chr9:122799448–122799842 Kif15-1110059G10Rik 20.3460.17 21.9660.65 3/4 HCP U
chr14:101869393–101869657* Kctd12 20.3460.63 22.0460.71 2/2 HCP U
chr4:133976469–133976747 Man1c1 20.4160.14 21.8660.62 2/2 HCP U
chr14:55525969–55526381 Cenpj 20.4860.13 21.8560.51 3/3 HCP U
chr19:6235862–6236239 Ppp2r5b 20.5060.31 22.5660.37 3/3 HCP I
chr16:43809152–43809407 2610015P09Rik-Qtrtd1 20.5660.28 22.3660.11 2/2 ICP U
chr4:61988560–61988857 Hdhd3 21.0360.11 22.0660.78 2/3 HCP U
chr9:123566265–123566427 Lztfl1 21.0860.04 22.5460.08 2/2 HCP U
chr5:139738113–139738428 Zfand2a 21.1560.93 22.5061.03 2/2 HCP U
chr7:138778679–138778997 Jakmip3 21.3460.14 22.7560.31 3/3 HCP U
chrX:142800291–142800547 Lrch2 21.6160.22 23.2360.40 2/2 HCP U
chr6:87777440–87777770 Rab43 21.6960.97 22.9161.33 2/3 HCP I
chr8:86180062–86,180,386 Ucp1 21.7860.66 23.0560.47 3/3 ICP I
chr1:60042576–60042951 Carf-Wdr12 21.8960.74 22.9660.43 2/3 HCP U
chr11:116347916–116348201 Sphk1 22.6360.39 23.8060.63 2/3 HCP U
chr4:135557672–135558059 Zfp46 22.7260.23 23.6560.55 2/3 ICP U
chr9:65857792–65858101 Ppib 22.9060.95 24.1661.23 3/3 HCP ND
GEN, genistein; DMR, differentially methylated region.
Position: GEN-mediated DMRs were identified by MspI fragment-based DNA methylation typing; these DMRs contain more than two consecutive probes with log2
(HpaII
r/McrBC
r) values unidirectionally different between the control and GEN-treated samples; the difference is greater than mean 6 3SD (Figure S6). Positions of each
DMR in the mouse genome assembly, February 2006, NCBI36/mm8, are shown.
Gene(s): the names of the gene(s) adjacent to the DMR are given. In some cases, a DMR contained two distinct, bi-directional promoters.
Control and GEN: the mean and standard deviation of the log2 (HpaII
r/McrBC
r) values for all probes within the DMR. Data were sorted from high to low for the Control
log2 (HpaII
r/McrBC
r) data.
DM/T: the ratio of the number of differentially methylated (DM) probes (the difference is greater than mean 6 3SD) to the total (T) number of probes within a DMR.
Class: promoter classification based on the CpG density. High CpG-density promoters (HCPs) contain at least one 500-bp region with GC content .0.55 and have a
ratio of observed to expected CpGs .0.6. Low CpG-density promoters (LCPs) lack the 500-bp GC-rich interval and the ratio of observed to expected CpGs is .0.4.
Intermediate CpG-density promoters (ICPs) have characteristics between HCPs and LCPs.
Ref.: the methylation levels of the various types of tissues of the corresponding region in human genome. Methylation levels of Methylated (M), Intermediately
methylated (I), and Unmethylated (U) derive from the Ensembl genome-wide DNA methylation resource (E-TABM-445). ND denotes a lack of available information about
the methylation level of the human counterpart.
*This DMR integrated two proximate probes that were similarly hypomethylated following GEN treatment; one probe resided in the MspI interval of chr14:101869393–
101869526, and the other was in chr14:101869523–101869657.
doi:10.1371/journal.pone.0019278.t002
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T-vector (Novagen, Madison,WI) and transformed into Escherichia
coli. Plasmid DNA from positive colonies was purified and
sequenced at the Tokyo Medical and Dental University Genome
Analysis Facility (Tokyo, Japan). Sequence and statistical analyses
were performed with the QUantification tool for Methylation
Analysis; http://quma.cdb.riken.jp/top/quma_main_j.html [9].
The statistical significance of the difference between two bisulfite
Table 3. Methylation levels of 16 DMRs in first exons that decreased following GEN exposure.
Position Gene(s) Control GEN DM/T Class Ref.
chr10:77446495–77446745 Aire 1.1060.13 21.0960.27 2/2 HCP I
chr2:152723597–152723825 Xkr7 20.3060.17 22.3560.37 2/2 HCP U
chr16:85691690–85692049 Adamts1 20.3960.32 21.7660.49 3/4 HCP U
chr4:138346306–138346788 Htr6 20.4060.36 21.5460.24 3/4 HCP I
chr7:127166953–127167145 Zfp747 20.4760.33 22.3460.01 2/2 HCP U
chr5:123655740–123655973 Mlxip 20.5660.11 22.2360.64 2/2 HCP U
chr6:115818559–115819049 Mbd4 20.7160.36 22.0660.73 4/5 HCP U
chr19:46185243–46185579 Elovl3 20.7360.33 22.2360.25 3/3 ICP U
chr18:59300968–59301135 Chsy3 21.0160.08 22.8060.04 2/2 HCP U
chr14:54635513–54635699 Tinf2 21.1260.20 22.9560.53 2/2 HCP U
chr18:86847315–86847672 Cbln2 21.2660.49 23.0460.62 2/2 HCP U
chr2:148098766–148098943 Thbd 21.3460.07 22.6360.01 2/2 HCP U
chr6:120330010–120330251 Kdm5a 21.3460.42 22.8360.68 2/2 HCP U
chr7:24007929–24008187 Zfp61 21.3560.18 22.8960.89 2/2 HCP ND
chr16:32339489–32339720 Tctex1d2 21.4860.59 23.1860.65 2/2 HCP U
chr5:75357283–75357527** Gsx2 21.9660.06 23.6860.20 2/2 HCP U
ibid.
**This DMR integrated two proximate probes that were similarly hypomethylated following GEN treatment; one probe resided in the MspI interval of chr5:75357283–
75357391, and the other probe resided in chr5:75357388–75357527.
doi:10.1371/journal.pone.0019278.t003
Table 4. Methylation levels of 19 DMRs in promoters that increased following GEN exposure.
Position Gene(s) Control GEN DM/T Class Ref.
chr13:114784255–114784514 Hspb3 20.2060.11 1.4060.41 2/2 ICP I
chr7:37276642–37276850 Zfp536 20.2760.29 0.9460.31 2/2 HCP U
chr11:95658180–95658391 Abi3-Gngt2 20.4260.07 1.1660.13 2/2 LCP M
chr15:74548037–74548493 4930572J05Rik 20.9960.33 0.0460.40 2/4 HCP U
chr14:119410569–119410820 Mbnl2 21.6260.55 20.0960.02 2/2 ICP U
chr9:106679759–106679960 Vprbp 21.6960.28 20.4360.09 2/2 HCP U
chr5:114705063–114705316 Mmab-Mvk 21.8260.01 20.2960.09 2/2 HCP U
chr16:92355095–92355340 Rcan1 21.8360.30 0.0260.08 2/2 HCP U
chr17:34172243–34172480 Notch4 21.8360.57 20.2060.46 2/2 LCP ND
chr3:5559307–5559483 Pxmp3 22.0060.25 20.5360.07 2/2 HCP U
chr7:28088184–28088486 Zfp36 22.1260.84 20.3560.30 2/3 HCP U
chr3:36743554–36744043 Exosc9 22.1460.89 21.0360.75 4/5 HCP ND
chr2:168281700–168281915 Nfatc2 22.2460.50 20.6160.47 2/2 HCP U
chr2:119238582–119238990 Exd1-1500003O03Rik 22.3760.32 20.8160.29 2/2 HCP U
chr19:8837816–8838035 Tmem223-Nxf1 22.3960.52 0.3160.16 2/2 HCP U
chr7:99357657–99357927 Rps3 22.5860.81 20.9360.23 2/3 HCP U
chr1:45870162–45870424 Slc40a1 22.6860.17 21.2260.43 2/2 ICP U
chr11:99961777–99962052 Krt19 23.5060.59 21.3360.33 2/2 HCP U
chr8:46831926–46832115 Cyp4v3 23.5560.47 21.4160.49 2/2 HCP U
ibid.
doi:10.1371/journal.pone.0019278.t004
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exact test.
Mouse embryos and adult tissues
All animal work was conducted in accordance with our
institution’s ethical guidelines for animal experiments. The
protocols for animal handling and treatment were reviewed and
approved (approval ID: S-22038) by the Animal Care and Use
Committee at Tokyo Medical University (Tokyo, Japan). Oocytes
were collected from the oviducts of C57BL/6J unmated female
mice that were treated for superovulation by intraperitoneal
injection of 5 U of pregnant mare serum gonadotropin followed
48 hr later by 5 U human chorionic gonadotropin. Twenty hours
after the second injection, oocytes were collected and fertilized in
vitro with C57BL/6J sperm. Zygotes were cultured in drops
containing M16 medium covered with mineral oil. To obtain
E6.75 and E10 embryos, two-cell embryos were transferred into
day-0.5 pseudo-pregnant ICR female mice the next day. For the
E6.75 stage, seven embryos were collected and genomic DNA was
isolated. For the E10 stage, genomic DNA samples were isolated
separately from two independent embryos. Genomic DNA was
isolated from adult mouse liver and lung with the QIAamp DNA
Mini Kit (QIAGEN).
Results
Identification of genistein-mediated DMRs
By day 10 of differentiation, ES cells give rise to a variety of
cells, including contracting cardiomyocytes. Exposure to 5 mM
genistein did not affect cardiomyocyte differentiation of ES cells,
indicating that treatment is not toxic (Figure S1). The analysis of
differentiation marker expression also indicated that 5 mM
genistein did not impair overall ES cell differentiation (Figure
S2). The global DNA methylation patterns in differentiated ES
cells with or without genistein treatment were analyzed with the
MFMT assay, which involves using either HpaII or McrBC to
dissect the methylation status of the end or interior CpGs for every
MspI fragment, respectively (Figure S3). Methylation levels are
reflected in the log2 (HpaII
resistant(r)/McrBC
resistant(r)) value for each
microarray probe (see Materials and Methods for details).
Genistein-mediated global changes in methylation levels were
assessed by the difference of the log2 (HpaII
r/McrBC
r) values
between genistein-treated and untreated (control) cells; a high
linear correlation was detected (Pearson correlation coefficient,
0.923) for the individual probes between the two datasets
(Figure 1). The log2 (HpaII
r/McrBC
r) values in the methylation
control regions were also similar in the control and genistein-
treated cells (Figures S4 and S5). Thus, although genistein
treatment did not alter the DNA methylation levels in most
regions detected by this assay, a subset of loci showed significant
differences in their methylation levels.
Next, the difference in the log2 (HpaII
r/McrBC
r) values for
each probe was calculated between the control and genistein-
treatment datasets (mean=0.048, standard deviation=0.379;
Figure S6). We selected probes with log2 (HpaII
r/McrBC
r)
differences larger than the mean consecutive difference; of these
probes, 1330 probes indicated regions hypomethylated following
genistein treatment (values above the upper limits of the mean
consecutive difference; mean plus three standard deviations),
whereas 952 probes reflected hypermethylation of regions
following genistein treatment (values below the lower limits of
the mean consecutive distance; mean minus three standard
deviations). However, the most pertinent methylation differences
are represented by the same directional log2 (HpaII
r/McrBC
r)
changes across multiple probes that are in close proximity to one
another on the genome; thus, we identified loci with more than
two differentially methylated probes. Out of 1330 hypomethyla-
tion and 952 hypermethylation probes, 223 (16.7%) and 117
(12.3%) probes, respectively, comprised sets of consecutive probes
within the same MspI fragment or adjoining MspI fragments.
Therefore, we regarded those MspI fragments as genistein-
mediated DMRs (Figure S7).
We identified a total of 149 DMRs, of which 54 regions were
more methylated and 95 regions were less methylated in genistein-
treated cells than in control cells (Table 1). Approximately half of
these DMRs (48.3%) were located in promoters, while the other
half (50.3%) occurred in gene-body regions. Fifty-one DMRs were
located in proximal promoter regions (less than 200 bp from TSS),
nine of which contained bi-directional promoters. We performed
gene ontology analysis using the DAVID Functional Annotation
tool for all 155 genes contained in DMRs, excluding one non-
coding RNA and two non-genic regions. Thirty-eight genes
(24.5%) were related to ‘‘gene expression’’ in the Gene Ontology
category (p,2.3610
24), while 25 (16.1%) and 7 genes (4.5%) were
related to ‘‘embryo’’ (p,0.016) and ‘‘fetal brain’’ (p,0.036),
respectively, in the Tissue_Expression category (Table S3). The
indicated p-values correspond to modified Fisher’s exact p-values
for gene-enrichment analysis (EASE score). No further specific
category was enriched in the genistein-mediated DMRs.
Seventy-four DMRs (mean length ,290 bp) were located in
proximal promoters and the first exon of genes (Tables 2–5). In
general, the sequences of the regions close to TSSs are relatively
conserved between human and mouse [10]. Furthermore, bisulfite
sequencing across matched tissues from human and mouse
revealed strongly conserved patterns of DNA methylation in
CpG island regions of SHANK3 promoter regions (including
Table 5. Methylation levels of 7 DMRs in first exons that increased following GEN exposure.
Position Gene(s) Control GEN DM/T Class Ref.
chr14:54742660–54742881 Ripk3 21.5860.14 20.1960.16 2/2 ICP I
chr2:156412702–156413107 Dlgap4 22.0560.60 20.9560.17 2/4 HCP I
chr14:43910711–43910948 Ptger2 22.2160.37 20.8460.36 2/2 HCP U
chr5:45957763–45957961 1600023N17Rik 22.2360.22 20.6160.13 2/2 HCP U
chr10:80105916–80106136 9030607L17Rik 22.7561.07 20.7860.54 2/2 HCP U
chr7:25336561–25336903 B3GNT8 22.8260.29 21.0761.42 2/2 ICP M
chr5:137970985–137971285 6430598A04Rik 23.0360.53 21.2660.39 3/3 HCP I
ibid.
doi:10.1371/journal.pone.0019278.t005
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methylation data from the corresponding human regions were
acquired from the available public resources [11,12]. Most DMRs
contained High CpG-density promoters (HCPs), and the somatic
methylation levels of their human counterparts were ‘‘unmethy-
lated.’’ Additionally, 10 intermediate CpG-density promoters
(ICPs) and 7 low CpG-density promoters (LCPs) were found in
genistein-mediated DMRs, with the somatic methylation levels of
the human counterparts varying from ‘‘unmethylated’’ to
‘‘methylated’’, including four counterparts (Ucp1, Sytl1, Hspb3,
and Ripk3) with ‘‘intermediate’’ methylation levels. Because ICPs
and LCPs are thought to be primary targets for DNA methylation
[5], these four promoters could possibly be DNA methylated as
well in mouse cells. This possibility prompted us to address the
question of how genistein influences DNA methylation levels of
ICP and LCP promoters in the early embryonic stages.
The Ucp1 promoter is differentially methylated upon
genistein treatment
From the genistein-mediated DMRs, we selected the Ucp1 and
Sytl1 promoter regions as representative of the ICP and LCP
promoters, respectively, for further analysis. First, we confirmed
the MFMT results on the Ucp1 gene by bisulfite sequencing
(Figure 2). We identified the MspI fragment at chr8: 86180062–
86180386 (NCBI36/mm8; from 2404 to 283 relative to the TSS)
as a genistein-mediated DMR because the mean log2 (HpaII
r/
McrBC
r) value in the genistein-treated sample (23.0560.47) was
significantly lower than in the control sample (21.7860.66)
(Student’s t test, p,0.0079) (Table 2, Figure 2A, B). Bisulfite
sequencing analysis from two independent experiments revealed
that methylation levels in the Ucp1 region (2285 to +180) were
significantly lower following genistein treatment (Figure 2C;
Fisher’s exact test, p,0.0192); the region analyzed by bisulfite
sequencing overlaps with the DMR identified by the MFMT
assay. Although genistein did not affect the CpG methylation level
at the 283 MspI site, the methylation level of the McrBC site at
2126 changed considerably (Figure 2C). Therefore, bisulfite
sequencing was consistent with the MFMT assay, indicating that
genistein treatment decreases the methylation levels of the Ucp1
promoter. This decrease was also confirmed using another ES cell
line, E14Tg2a (Figure 2D).
De novo methylation of the Ucp1 promoter
Next, we asked whether the Ucp1 promoter region underwent de
novo DNA methylation during ES cell differentiation. Methylation
levels were analyzed by bisulfite sequencing. The Ucp1 promoter
region was unmethylated before differentiation (day 0); the
methylation levels increased until day 4 and decreased thereafter,
and there was no significant difference in the methylation level of
the Ucp1 promoter between control and genistein-treated cells on
day 4 (Fisher’s exact test, p,0.43) (Figure 3A). While the
developmental stage of day 4 ES cell differentiation corresponds
to the gastrula stage of the early embryo [13], the day 10 ES cell
differentiation stage possibly corresponds to E8-10 embryos, which
are initiating early organogenesis. We observed that the methyl-
ation levels of the Ucp1 promoter in early normal embryos were
much higher at E6.75 (gastrula) than at E10 (early organogenesis)
(Figure 3B), suggesting that the methylation level of the Ucp1
promoter is transiently elevated by the time of the gastrulation
stage, but is subsequently demethylated in the course of further
development.
The Sytl1 promoter region is differentially methylated
following genistein treatment
We also used bisulfite sequencing to investigate the methylation
states of another genistein-mediated DMR, the Sytl1 promoter
(Figure 4). We identified the MspI fragment at chr4: 132534712–
132535246 (281 to +451 relative to the TSS) as a genistein-
mediated DMR because the mean log2 (HpaII
r/McrBC
r) value in
the MFMT analysis of the genistein-treated samples (21.1360.44)
was significantly lower than in the control samples (20.0360.48)
(Student’s t test, p,0.027)(Table 2, Figures 4A, B). Bisulfite
sequencing of the region from 2221 to +220 (7 CpGs; Figure 4C)
in day 0, day 4, and day 10 CCE ES differentiation samples
revealed that the Sytl1 promoter was moderately methylated on
day 0. The methylation level increased until day 4 in a manner
that genistein treatment did not affect. The methylation level had
decreased by day 10, but of note, the methylation decrease
occurred at different positions in the control (+66) and genistein-
treated (223) cells. The overall methylation level following
genistein treatment was lower than in control cells on day 10.
The CpG methylation level at the HpaII site at 281 was also
slightly lower in genistein-treated cells than in control cells,
suggesting that the MFMT assay could detect the slight difference
in methylation levels of this HpaII site. Thus, genistein treatment
influenced the methylation levels of the Ucp1 and Sytl1 promoters
in a similar fashion.
Discussion
Epidemiological and animal studies have demonstrated that
nutrition and other environmental stimuli influence prenatal
developmental pathways, thereby inducing permanent changes in
metabolism and chronic disease susceptibility. Epigenetic alter-
ation caused by the intrauterine environment may partly explain
trait diversity, including disease phenotypes. Nevertheless, little is
known about the causal relationship between the intrauterine
environment and epigenetic dysregulation, probably because
somatic methylome establishment consists of multiple develop-
mental steps. Considerable attention has been paid to alterations
in the fetal epigenome induced by nutritional stimuli in utero,a s
clearly demonstrated by changes in the methylation levels of the
A
vy allele resulting from maternal intake of genistein [1], bisphenol
A [14], or methyl donors [15,16]. These somatic epigenetic
Figure 2. Methylation levels of the Ucp1 promoter decreased following genistein (GEN) treatment. A: The genomic location and other
features of the mouse Ucp1 promoter are shown. The sequence identifier containing the Ucp1 promoter region covers chr8: 86179166–86180966
(NCBI36/mm8 assembly), including a single nucleotide polymorphism, rs8257105, that is A/A in 129 and G/G in C57BL/6. In embryonic stem cell lines
CCE and E14Tg2a with rs8257107 (A/A), the CpG and MspI recognition sequences are lost. The MspI fragment at chr8: 86180062–86180386 (from
2404 to 283 relative to TSS) was identified as a GEN-mediated differentially methylated region (DMR) by MspI fragment-based DNA methylation
typing. There are three NimbleGen probes (orange rectangles) in the DMR; the region from 2285 to +180 (magenta rectangle) was analyzed by
bisulfite sequencing. B: The means and standard deviations for the log2 (HpaII
r/McrBC
r) values of the three probes within the DMR (2404 to 283) are
shown; the values from the GEN-treated samples (23.0560.47) were significantly lower than in the control samples (21.7860.66; p,0.0079,
Student’s t test). C and D: Bisulfite sequencing of CpGs was carried out for day 10 differentiation samples from CCE and E14Tg2a embryonic stem cell
lines to compare methylation levels between control cells and cells treated with 5 mM GEN. Black and white circles indicate methylated and
unmethylated CpGs, respectively.
doi:10.1371/journal.pone.0019278.g002
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differentiation in the early embryo [3]. Therefore, it is important
to elucidate the effects of environmental modification on the fetal
epigenome, particularly in this early developmental stage.
Because the in vitro ES cell differentiation by means of embryoid
body formation is widely used for analysis of early embryogenesis
around the post-implantation period, we compared the changes in
DNA methylation states of the differentiated ES cell cultures
between control and genistein-supplemented conditions. We
added genistein to ES cell cultures at a physiological concentration
of 5 mM without impairing the overall differentiation for at least 10
days (Figures S1 and S2). As expected, genistein treatment did not
affect global DNA methylation patterns (Figure 1), but we could
identify 74 regions proximal to TSSs that were differentially
methylated following genistein treatment (Tables 2–5). We
performed gene ontology analysis using the DAVID Functional
Figure 3. Developmental dynamics of Ucp1 methylation and the influence of genistein (GEN). Methylation levels were analyzed by
bisulfite sequencing. The black inlay is the mean methylation level of each CpG, and the left panel contains the number of sequenced clones and the
mean methylation level of all CpGs. A: The methylation levels of the Ucp1 promoter dynamically changed during embryonic stem (ES) cell
differentiation. In undifferentiated (day 0) ES cells, most CpGs in the Ucp1 promoter were unmethylated. Although the methylation levels increased
by day 4, there was no significant difference between methylation levels in control (24.7%) and GEN-treated samples (27.3%; p,0.43, Fisher’s exact
test). On day 10, the methylation level of the Ucp1 promoter in GEN-treated cells (14.7%) was significantly lower than in control cells (20.7%;
p,0.0192), and the overall methylation levels were decreased on day 10 compared with day 4. B: The methylation levels of the Ucp1 promoter in
early embryos are shown. As the embryo developed, the methylation level declined between E6.75 and E10.
doi:10.1371/journal.pone.0019278.g003
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significantly enriched in the genistein-mediated DMRs. This result
may be attributable to an effect of genistein on a general or
unspecified pathway in the early embryonic stage rather than on
differentiated functions.
We also investigated in detail the methylation states of the Ucp1
and Sytl1 promoters (Figures 2–3 and 4, respectively). The
initiation time for de novo methylation varies from one promoter
to another, and some promoter methylation is erased during
somatic development [5]. Similarly, we found that the methylation
levels of the Ucp1 and Sytl1 promoters dynamically change within a
short period of early embryonic development. De novo methylation
and subsequent demethylation starts early for these promoters.
Methylation of the Ucp1 promoter substantially decreased during
the E6. 75-10 stage of the embryo. Similarly, the Ucp1 and Sytl1
promoters underwent de novo DNA methylation until day 4 of ES
differentiation, and were subsequently demethylated by day 10
(Figures 3 and 4). It was interesting that genistein treatment did
not affect de novo methylation, as peak methylation levels did not
differ between control and genistein samples; in contrast, genistein
treatment changed methylation levels in the later stage (Figures 3
and 4). Because early tissue precursor cells appear after
gastrulation, it is tempting to speculate that genistein changes
the methylation prototype of those precursor cells. The increase in
the expression level of ERa (Esr1) could partly explain the
genistein sensitivity on day 10 observed here (Figure S8), but it
remains to be further elucidated whether nuclear receptors such as
ERa and/or ERb are involved in alteration of DNA methylation
levels in genistein-mediated DMRs.
Ucp1 functions as a mitochondrial uncoupling protein in brown
adipose tissue; the CpG methylation level in the Ucp1 enhancer
(especially at the CRE3 site) is remarkably low in brown adipose
tissue cells [17]. On the other hand, promoter methylation is
known to be important for Ucp1 silencing in white adipose tissue
[17,18]. In this study, upon ES differentiation, the Ucp1 enhancer
gained methylation, and genistein treatment rather amplified this
increase in methylation levels (Figure S9). Thus, the genistein-
mediated decrease in methylation levels was restricted only to the
promoter region. Mitochondrial biosynthesis is activated upon
cell-fate commitment during the course of ES cell differentiation
[19]. In addition, genistein and other isoflavones promote
mitochondrial biogenesis [20]. These issues could be relevant to
the regulation of Ucp1 methylation states and warrant further
studies.
Sytl1 functions as a Rab27 effector protein in a wide variety of
cells [21,22,23]. Genistein treatment also altered the methylation
patterns of the Sytl1 promoter (Figure 4). In contrast to the Ucp1
promoter, the decrease in methylation following genistein
treatment occurred preferentially at the 223 CpG site. To study
the somatic methylation pattern of the Sytl1 promoter, DNA was
extracted from adult mouse liver and lung and analyzed (Figure
S10). The methylation patterns characteristic of hypomethylation
at CpG 223 were observed in the genistein-exposed ES cells on
day 10 as well as in adult somatic tissues. Again, genistein
treatment lowered the methylation level of the Sytl1 promoter,
which could lead to the formation of a somatic DNA methylation
pattern.
It is unclear whether the genistein-mediated differential
methylation detected at the early embryonic stage in intrinsic
genes (Ucp1 and Sytl1) persists until later stages of development.
Our demonstration that the methylation levels changed following
genistein exposure during the post gastrulation period is in accord
with the idea that the genistein-mediated methylation changes in
A
vy are generated before germ layer differentiation. The epigenetic
changes established in tissue stem cells that start to appear at the
post-gastrulation period may persist until the later stages of
development, or they may be modified during terminal differen-
tiation of individual tissues. The methylation dynamics at
sequential stages of development must be further clarified by
spatiotemporal investigations.
We compared our genistein-mediated DMRs with the DMRs
previously found in intrauterine growth retardation (IUGR)
neonates [24]. There were no overlaps in the lists for top genes
between genistein-mediated DMRs and IUGR DMRs. However,
both types of DMRs seemed to share important similarities. First
of all, the magnitude of DNA methylation changes for both types
of DMRs was markedly less than many tissue-specific or cancer-
related differences. In addition, long-range changes in methylation
levels did not occur over a gene locus in both DMRs. Rather, the
methylation changes specifically occurred at particular sites among
multiple alternative promoters in some genes. As for Ucp1 and
Sytl1, they do not seem to have alternative promoters, yet the
promoter methylation levels also were changed in the IUGR
neonates, albeit in the opposite direction of genistein treatment
(higher methylation in IUGR than in control samples) [24]. It
would be interesting to investigate whether these two genes are
commonly sensitive to intrauterine environmental factors.
To the best of our knowledge, this study is the first report of the
effects of genistein treatment on DNA methylation patterns
during ES cell differentiation. We demonstrated that genistein
perturbed methylation regulation subsequent to de novo methyl-
ation, resulting in alteration of the methylation levels of a subset
of promoters in an early embryonic stage. In the future, we plan
to investigate how this alteration influences lifetime methylation
patterns.
Supporting Information
Figure S1 Treatment with 5 mM genistein (GEN) does
not impede cardiomyocyte differentiation of embryonic
stem cells. Five culture conditions were tested for cardiomyocyte
differentiation: no additives, dimethyl sulfoxide (DMSO) solvent
only, 1 mM GEN, 5 mM GEN, and 10 mM GEN. Embryoid body
(EB) formation was induced by hanging-drop culture (one drop
contains 20 ml cell suspension at 4610
4 cells/ml) without leukemia
inhibitory factor for two days, followed by two days of suspension
culture. The EBs were transferred to a 100-mm gelatinized dish
under individual culture conditions. Differentiation was deter-
mined by microscopic inspection of 20 EB outgrowths for each
plate. The number of EBs containing contracting cardiomyocytes
Figure 4. The methylation levels of the Sytl1 promoter decreased following genistein (GEN) treatment. A: The genomic location and
other features of the mouse Sytl1 promoter are shown. The sequence identifier containing the Sytl1 promoter covers chr4: 132534642–132536442
(NCBI36/mm8 assembly). MspI fragment-based DNA methylation typing identified the MspI fragment at chr4: 132534712–132535246 (281 to +451
relative to TSS) as a GEN-mediated differentially methylated region (DMR). The simple repeat (GAG)n is found in the region (from 251 to 224). Five
probes reside in the DMR (orange rectangles); the region from 2221 to +220 (magenta rectangle) was analyzed with bisulfite sequencing. B: The
mean and standard deviations for the log2 (HpaII
r/McrBC
r) values of the five probes within the DMR (281 to +451) are shown; the value in the sample
treated with 5 mM GEN (21.1360.44) was lower than that in the control sample (20.0360.48; p,0.027, Student’s t test). C: Bisulfite sequencing of
CpGs was carried out for day 0, day 4, and day 10 of embryonic stem cell differentiation samples to monitor the effect of GEN treatment.
doi:10.1371/journal.pone.0019278.g004
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ocyte differentiation up to concentrations of 5 mM.
(TIF)
Figure S2 Marker gene expressions during embryonic
stem cell differentiation. The expression levels of differenti-
ation marker genes were analyzed by real-time PCR assay.
Regardless of genistein treatment, the decline of Pou5f1 (a
pluripotency marker) and the transient elevation of T (a
gastrulation marker) expression occurred, indicating that normal
ES cell differentiation was proceeding. The elevated expression of
ectoderm markers (Fgf5 and Wnt3a) was similarly observed both in
control and genistein-treated cells on day 4. The expression of
mesoderm (Pdgfra, Tbx5) and endoderm (GATA4, GATA6) markers
was also similarly increased in both conditions on day 10.
(TIF)
Figure S3 Schematic outlines for MspI fragment-based
DNA methylation typing (MFMT) assay and NimbleGen
probe selection. For MFMT, probes were selected from the
NimbleGen promoter array probe set. Probes carrying MspI sites
present short lengths for annealing to the amplified PCR products;
therefore, NimbleGen probes carrying MspI sequences were
excluded from further analysis. Because the PCR products were
100–1000 bp long, probes were selected that were enclosed by two
MspI sites separated by that size range. Genomic DNA was
initially digested by MspI and ligated to an oligonucleotide
adaptor pair. The ligated products were digested by a methylation-
sensitive restriction enzyme (HpaII or McrBC), and the digestion-
resistant fragments were amplified by PCR. If the CpG at the end
of the MspI fragment was unmethylated, the adaptor-ligated
product was digested by the HpaII enzyme (the red zigzag lines in
the left column). If the MspI fragment contained McrBC target
CpGs and those CpGs were methylated, the adaptor-ligated
product was digested by the McrBC enzyme (the red zigzag lines
in the right column). However, HpaII-resistant and McrBC-
resistant fragments remained and were labeled with Alexa 555 or
647, respectively, and cohybridized on a mouse promoter tiling
array. The log2 (HpaII
r/McrBC
r) values were calculated for
selected probes for the MFMT assay.
(TIF)
Figure S4 Validation studies of the MFMT assay using
the methylation control regions. The methylation control
regions were selected based on the published data reported in [6]
(see Materials and Methods). The mean log2 (HpaII
r/McrBC
r)
values of control and genistein-treated samples in the methylation-
positive regions are plotted with blue dots, while those in the
methylation-negative regions are indicated by red dots. The gene
names for all seven positive controls and the 18 negative controls
with lower mean log2 (HpaII
r/McrBC
r) values are shown. While
the mean log2 (HpaII
r/McrBC
r) values for methylation-positive
regions are above 0, those for methylation-negative regions are
below 0 both in control and genistein-treated cells.
(TIF)
Figure S5 Probe positions and their mean log2 (HpaII
r/
McrBC
r) values in the methylation-positive (hyper-
methylated) and –negative (hypomethylated) regions.
Two methylation-positive (Dazl (A), Spo11 (B)) and two methyla-
tion-negative (Dhfr (C), Psmd1 (D)) control regions, the examples in
Figure S4, were analyzed. For control samples and samples treated
with 5 mM genistein (GEN), the means and standard deviations for
the log2 (HpaII
r/McrBC
r) values of all probes within the fragment
are shown.
(TIF)
Figure S6 Distribution of log2 (HpaII
r/McrBC
r) differ-
ences between control and genistein (GEN)-treated
samples. The log2 (HpaII
r/McrBC
r) measurement from the
GEN-treated dataset was subtracted from the corresponding
control value for each probe. The 1330 probes above the upper
limits of the mean consecutive difference (mean plus three
standard deviations; right arrow) were regarded as hypomethy-
lated probes under GEN treatment, while the 952 probes below
the lower limits of the mean consecutive difference (mean minus
three standard deviations; left arrow) were hypermethylated.
(TIF)
Figure S7 Schematic outlines of the identification of a
genistein (GEN)-mediated differentially methylated re-
gion (DMR). A. There is a high linear correlation between the log2
(HpaII
r/McrBC
r) values from the control and 5 mMG E N - t r e a t e d
samples (mean=0.048, standard deviation=0.379). We identified
1330 hypomethylated probes and 952 hypermethylated probes, a
subset of which localized within close proximity of a given genomic
position. In a model scheme, three differentially methylated probes
(black rectangles) appear in a region with a unique sequence identifier
(SEQ_ID), and two consecutive probes are located within the same
MspI fragment. B. We defined a genistein (GEN)-mediated
differentially methylated region (DMR) as a MspI fragment within
which more than two consecutive probes show the same directional
log2 (HpaII
r/McrBC
r) changes. The example of a GEN-mediated
DMR in the Notch3 promoter is shown. Consecutive probes 1, 2, and
3 were extracted from the set of 1330 hypomethylated probes; these
three probes localized to the same MspI fragment in the Notch3
promoter region. Therefore, this MspI fragment region was identified
as one of the GEN-mediated DMRs (Table 2).
(TIF)
Figure S8 Expression levels of Esr1 and Esr2. The
expression levels of Esr1 and Esr2 genes were analyzed by real-
time PCR assay. The expression of Esr1 increased as ES cells
differentiated, while the Esr2 expression level was constantly low
throughout the course of ES cell differentiation.
(TIF)
Figure S9 Hypermethylation of the Ucp1 enhancer was
not changed by genistein (GEN) treatment. Bisulfite
sequencing of CpGs in the Ucp1 enhancer region was performed
for day 0 and day 10 cells either unexposed (control) or exposed to
5 mM GEN. The mean methylation level of all CpGs is shown in
the left panel. The core sequences (CGTCA) of the CRE3 and
CRE2 sites coincide with the CpGs at 22581 and 22540. The
methylation level of the enhancer region, including the CRE sites,
was higher at day 10 than at day 0, regardless of GEN treatment.
(TIF)
Figure S10 Methylation patterns of the Sytl1 promoter
in somatic tissues in adult mice. Bisulfite sequencing of
CpGs in the Sytl1 promoter region was carried out for liver and
lung tissue cells of an adult female mouse. The analyzed region is
the same as that depicted in Figure 4. The methylation level at the
223 CpG site is consistently low in both tissues.
(TIF)
Table S1 Primers and Universal Probe Library probes
for real-time PCR. Detailed information for Universal Probe
Library probes is available online at the ‘‘Universal Probe Library
Assay Design Center’’ of Roche Applied Science.
(DOC)
Table S2 Primers used for bisulfite sequencing.
(DOC)
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contained within differentially methylated regions.
(DOC)
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